Order Article Reprints

Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S on Behalf of the K-877 Study Group. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences. 2019; 20(3):706. https://doi.org/10.3390/ijms20030706

Yokote, Koutaro, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Hideki Suganami, and Shun Ishibashi on Behalf of the K-877 Study Group. 2019. "Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment" International Journal of Molecular Sciences 20, no. 3: 706. https://doi.org/10.3390/ijms20030706

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S., on Behalf of the K-877 Study Group. (2019). Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences, 20(3), 706. https://doi.org/10.3390/ijms20030706